TARS

Tarsus Pharmaceuticals, Inc.

Healthcare
Biotechnology
$3.41B market cap

Forecast run · Sep 18, 2026Upside rank 1061 of 3,150

Model Signal

ForecastQ Daily Probabilities

37.9%

35.3%

14.1%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$79.31

Price target$100.40

Implied move+26.6%

Analysts10

ForecastQ Portfolios

TARS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.